ArticleMolecular and clinical oncology2014

Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials.

Naijun Lei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.